Skip to main content
JOHNSON & JOHNSON logo

JOHNSON & JOHNSON — Investor Relations & Filings

Ticker · JNJ ISIN · US4781601046 LEI · 549300G0CFPGEF6X2043 US Manufacturing
Open in API
Filings indexed 3,105 across all filing types
Latest filing 2016-02-25 Capital/Financing Update
Country US United States of America
Listing US JNJ

About JOHNSON & JOHNSON

https://www.jnj.com/

Johnson & Johnson is a healthcare company that operates through two primary segments: Innovative Medicine and MedTech. The Innovative Medicine division is focused on the research, development, and delivery of new treatments for complex diseases in areas such as oncology, immunology, neuroscience, and cardiopulmonary conditions. The MedTech segment develops and provides a broad portfolio of medical technologies and solutions. It innovates in fields including surgery, orthopaedics, vision, and interventional solutions, aiming to create smarter, less invasive, and more personalized healthcare treatments. The company's mission is to address significant health challenges through science-based innovation at the intersection of biology and technology.

Recent filings

Filing Released Lang Actions
424B3
Capital/Financing Update Classification · 100% confidence The document is a preliminary prospectus supplement filed pursuant to Rule 424(b)(3) related to a debt securities offering by Johnson & Johnson. It includes detailed terms of the notes, risk factors, use of proceeds, underwriting information, and references to SEC filings such as the annual report on Form 10-K. The document is a registration and offering prospectus supplement, which is a capital markets financing document describing new debt issuance. It is not a financial report, earnings release, or management discussion. It is clearly a capital/financing update related to the issuance of new notes. Therefore, the appropriate classification is Capital/Financing Update (CAP). The document length and content support a high confidence in this classification.
2016-02-25 English
10-K
Annual Report FY 2016
2016-02-24 English
Director's Dealing 2016
Director's Dealing
2016-02-19 English
AUTO-GENERATED PAPER DOCUMENT
Regulatory Filings
2016-02-17 English
SCHEDULE 13G/A FOR NEVRO CORP.
Major Shareholding Notification
2016-02-12 English
SCHEDULE 13G
Major Shareholding Notification
2016-02-12 English

Browse filings by year

27 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.